S&P 500   4,252.15 (+0.54%)
DOW   33,078.39 (+0.23%)
QQQ   358.93 (+1.13%)
AAPL   173.17 (+0.45%)
MSFT   318.27 (+1.56%)
META   304.30 (+1.12%)
GOOGL   134.68 (+1.70%)
AMZN   126.41 (+1.36%)
TSLA   257.70 (+4.53%)
NVDA   437.86 (+0.62%)
NIO   8.76 (+1.74%)
BABA   84.09 (-0.53%)
AMD   102.45 (+2.37%)
T   14.59 (-1.29%)
F   12.04 (-0.25%)
MU   67.86 (+0.04%)
CGC   0.77 (+12.56%)
GE   109.13 (+1.27%)
DIS   79.57 (+0.04%)
AMC   8.06 (+2.68%)
PFE   33.54 (-1.06%)
PYPL   58.38 (+1.88%)
NFLX   376.92 (+0.05%)
S&P 500   4,252.15 (+0.54%)
DOW   33,078.39 (+0.23%)
QQQ   358.93 (+1.13%)
AAPL   173.17 (+0.45%)
MSFT   318.27 (+1.56%)
META   304.30 (+1.12%)
GOOGL   134.68 (+1.70%)
AMZN   126.41 (+1.36%)
TSLA   257.70 (+4.53%)
NVDA   437.86 (+0.62%)
NIO   8.76 (+1.74%)
BABA   84.09 (-0.53%)
AMD   102.45 (+2.37%)
T   14.59 (-1.29%)
F   12.04 (-0.25%)
MU   67.86 (+0.04%)
CGC   0.77 (+12.56%)
GE   109.13 (+1.27%)
DIS   79.57 (+0.04%)
AMC   8.06 (+2.68%)
PFE   33.54 (-1.06%)
PYPL   58.38 (+1.88%)
NFLX   376.92 (+0.05%)
S&P 500   4,252.15 (+0.54%)
DOW   33,078.39 (+0.23%)
QQQ   358.93 (+1.13%)
AAPL   173.17 (+0.45%)
MSFT   318.27 (+1.56%)
META   304.30 (+1.12%)
GOOGL   134.68 (+1.70%)
AMZN   126.41 (+1.36%)
TSLA   257.70 (+4.53%)
NVDA   437.86 (+0.62%)
NIO   8.76 (+1.74%)
BABA   84.09 (-0.53%)
AMD   102.45 (+2.37%)
T   14.59 (-1.29%)
F   12.04 (-0.25%)
MU   67.86 (+0.04%)
CGC   0.77 (+12.56%)
GE   109.13 (+1.27%)
DIS   79.57 (+0.04%)
AMC   8.06 (+2.68%)
PFE   33.54 (-1.06%)
PYPL   58.38 (+1.88%)
NFLX   376.92 (+0.05%)
S&P 500   4,252.15 (+0.54%)
DOW   33,078.39 (+0.23%)
QQQ   358.93 (+1.13%)
AAPL   173.17 (+0.45%)
MSFT   318.27 (+1.56%)
META   304.30 (+1.12%)
GOOGL   134.68 (+1.70%)
AMZN   126.41 (+1.36%)
TSLA   257.70 (+4.53%)
NVDA   437.86 (+0.62%)
NIO   8.76 (+1.74%)
BABA   84.09 (-0.53%)
AMD   102.45 (+2.37%)
T   14.59 (-1.29%)
F   12.04 (-0.25%)
MU   67.86 (+0.04%)
CGC   0.77 (+12.56%)
GE   109.13 (+1.27%)
DIS   79.57 (+0.04%)
AMC   8.06 (+2.68%)
PFE   33.54 (-1.06%)
PYPL   58.38 (+1.88%)
NFLX   376.92 (+0.05%)
NASDAQ:BCEL

Atreca (BCEL) Stock Forecast, Price & News

$0.23
+0.00 (+0.04%)
(As of 12:44 PM ET)
Compare
Today's Range
$0.23
$0.25
50-Day Range
$0.23
$0.98
52-Week Range
$0.23
$2.05
Volume
43,682 shs
Average Volume
161,170 shs
Market Capitalization
$9.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.75

Atreca MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
4,416.8% Upside
$10.75 Price Target
Short Interest
Bearish
9.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$9,085 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.64) to ($0.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars


BCEL stock logo

About Atreca (NASDAQ:BCEL) Stock

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

BCEL Price History

BCEL Stock News Headlines

BREAKING: The truth about war with China
Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.
Stifel Downgrades Atreca Inc - (BCEL)
BREAKING: The truth about war with China
Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.
Stifel Nicolaus Reaffirms Their Buy Rating on Atreca (BCEL)
Atreca (BCEL) Gets a Buy from H.C. Wainwright
Atreca (NASDAQ: BCEL)
Stifel Nicolaus Sticks to Their Buy Rating for Atreca (BCEL)
See More Headlines
Receive BCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atreca and its competitors with MarketBeat's FREE daily newsletter.

BCEL Company Calendar

Last Earnings
8/10/2023
Today
10/04/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCEL
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.75
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+4,416.8%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-97,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.01 per share

Miscellaneous

Free Float
34,856,000
Market Cap
$9.35 million
Optionable
Not Optionable
Beta
1.24
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. John A. Orwin M.B.A. (Age 58)
    Pres, CEO, Director & Principal Financial Officer
    Comp: $927.03k
  • Dr. Tito A. Serafini Ph.D. (Age 60)
    Founder, Chief Strategy Officer & Director
    Comp: $665.5k
  • Dr. Stephen E. Gould Ph.D. (Age 58)
    Chief Scientific Officer
    Comp: $380.52k
  • Mr. Rick Ruiz (Age 59)
    Principal Accounting Officer
  • Ms. Courtney J. Phillips J.D. (Age 48)
    Gen. Counsel & Corp. Sec.
  • Dr. Philippe C. Bishop M.D. (Age 58)
    Chief Medical Officer













BCEL Stock - Frequently Asked Questions

Should I buy or sell Atreca stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BCEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCEL, but not buy additional shares or sell existing shares.
View BCEL analyst ratings
or view top-rated stocks.

What is Atreca's stock price forecast for 2023?

5 brokers have issued 1-year target prices for Atreca's stock. Their BCEL share price forecasts range from $4.00 to $25.00. On average, they predict the company's share price to reach $10.75 in the next year. This suggests a possible upside of 4,416.8% from the stock's current price.
View analysts price targets for BCEL
or view top-rated stocks among Wall Street analysts.

How have BCEL shares performed in 2023?

Atreca's stock was trading at $0.8006 at the beginning of the year. Since then, BCEL shares have decreased by 70.3% and is now trading at $0.2380.
View the best growth stocks for 2023 here
.

When is Atreca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our BCEL earnings forecast
.

How were Atreca's earnings last quarter?

Atreca, Inc. (NASDAQ:BCEL) posted its earnings results on Thursday, August, 10th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.07.

What is John Orwin's approval rating as Atreca's CEO?

6 employees have rated Atreca Chief Executive Officer John Orwin on Glassdoor.com. John Orwin has an approval rating of 100% among the company's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Atreca to a friend.

What other stocks do shareholders of Atreca own?
When did Atreca IPO?

(BCEL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel served as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.

What is Atreca's stock symbol?

Atreca trades on the NASDAQ under the ticker symbol "BCEL."

How do I buy shares of Atreca?

Shares of BCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atreca's stock price today?

One share of BCEL stock can currently be purchased for approximately $0.24.

How much money does Atreca make?

Atreca (NASDAQ:BCEL) has a market capitalization of $9.35 million. The company earns $-97,160,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis.

How can I contact Atreca?

Atreca's mailing address is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. The official website for the company is www.atreca.com. The company can be reached via phone at (650) 595-2595 or via email at ir@atreca.com.

This page (NASDAQ:BCEL) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -